Abstract:Pertussis is a respiratory infectious disease that has been resurged during the last decades. The change from the traditional multi-antigen whole-cell pertussis (wP) vaccines to acellular pertussis (aP) vaccines that consist of a few antigens formulated with alum, appears to be a key factor in the resurgence of pertussis in many countries. Though current aP vaccines have helped to reduce the morbidity and mortality associated with pertussis, they do not provide durable immunity or adequate protection against the disease caused by the current circulating strains of Bordetella pertussis, which have evolved in the face of the selection pressure induced by the vaccines. Based on the hypothesis that a new vaccine containing multiple antigens could overcome deficiencies in the current aP vaccines, we have designed and characterized a vaccine candidate based on outer membrane vesicle (OMVs). Here we show that the OMVs vaccine, but not an aP vaccine, protected mice against lung infection with a circulating pertactin (PRN)-deficient isolate. Using isogenic bacteria that in principle only differ in PRN expression, we found that deficiency in PRN appears to be largely responsible for the failure of the aP vaccine to protect against this circulating clinical isolates. Regarding the durability of induced immunity, we have already reported that the OMV vaccine is able to induce long-lasting immune responses that effectively prevent infection with B. pertussis. Consistent with this, here we found that CD4 T cells with a tissue-resident memory (TRM) cell phenotype (CD44+CD62LlowCD69+ and/or CD103+) accumulated in the lungs of mice 14 days after immunization with 2 doses of the OMVs vaccine. CD4 TRM cells, which have previously been shown to play a critical role sustained protective immunity against B. pertussis, were also detected in mice immunized with wP vaccine, but not in the animals immunized with a commercial aP vaccine. The CD4 TRM cells secreted IFN-γ and IL-17 and were significantly expanded through local proliferation following respiratory challenge of mice with B. pertussis. Our findings that the OMVs vaccine induce respiratory CD4 TRM cells may explain the ability of this vaccine to induce long-term protection and is therefore an ideal candidate for a third generation vaccine against B. pertussis.

Protective immunity against Bordetella pertussis by a recombinant DNA vaccine and the effect of coinjection with a granulocyte-macrophage colony stimulating factor gene.

Granulocyte-macrophage Colony-Stimulating Factor DNA Prime-Protein Boost Strategy to Enhance Efficacy of a Recombinant Pertussis DNA Vaccine

Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines

Subcutaneous administration of a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis induces mucosal and systemic immune responses

The mature c-terminal domain of filamentous hemagglutinin is sufficient to provide protection against Bordetella pertussisin the murine nasal cavity

[Immunogenicity and Protective Efficacy of Pertactin Recombinants Against Bordetella Bronchiseptica Challenge].

A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis

Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective against Bordetella pertussis respiratory infection in mice

Plga Nano/Micro Particles Encapsulated with Pertussis Toxoid (ptd) Enhances Th1/Th17 Immune Response in A Murine Model

Immunogenicity of Recombinant Protective Antigen and Efficacy Against Intranasal Challenge with Bordetella Bronchiseptica

A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against Bordetella pertussis, Including Pertactin Deficient Strains

Mucosal and systemic immune responses elicited by recombinant Lactococcus lactis expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis

Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells

Immunogenicity of Recombinant R1 Region Antigen of Pertactin and Its Efficacy Against Bordetella Bronchiseptica Challenge

Immunization with an mRNA DTP vaccine protects against pertussis in rats

Study on Purification and Biological Characteristics of Pertactin from Bordetella Pertussis

A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis

[Protecting Mice from Fatal Bordetella Bronchiseptica Infection by Immunization with Recombinant Pertactin Antigens].

Intranasal acellular pertussis vaccine provides mucosal immunity and protects mice from Bordetella pertussis

Multivalent mRNA-DTP vaccines are immunogenic and provide protection from Bordetella pertussis challenge in mice

BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models